AM25-MN-28-L - Plasma Failure in Multiple Organ Dysfunction Syndrome (MODS)

Monday, October 27, 2025

3:45 PM - 4:45 PM PT

Location: 31

Program Chair(s)

JH

Jan C. Hofmann, MD, MPH, MSc (he/him/his)

Clinical Professor
University of California, San Francisco
Mill Valley, California

Disclosure(s): No relevant disclosure to display

Speaker(s)

Jay S. Raval, MD

Professor, Department. of Pathology and Laboratory Medicine
University of Vermont Medical Center
Burlington, Vermont

Disclosure(s): No relevant disclosure to display
MF

Matthew J. Foglia, MD, PhD (he/him/his)

Assistant Professor
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Disclosure(s): No financial relationships to disclose

Proposed Session Description: This session will update the attendee on the overall evidence (9 RCTs and multiple propensity-score matched cohort studies) and recent analysis (6 systematic reviews/meta-analyses since 2022) on the efficacy of therapeutic plasma exchange (TPE) in sepsis/multi-organ failure (MOF) and multiple organ dysfunction syndrome (MODS); in addition, the 2023 ASFA Guidelines will be reviewed. Second, the application of TPE in the treatment of trauma-induced coagulopathy (TIC) will be introduced and explored. Finally, the concept of "plasma failure" will be delineated in the setting of sepsis/MOF and MODS as a useful model in defining the potential role of TPE as a non-selective platform in treating acute inflammation, immune dysregulation, and coagulopathy.

Learning Objectives:

Evaluate the effectiveness of therapeutic plasma exchange (TPE) treatment in sepsis/MOF and MODS with respect to inflammatory biomarkers and 28-day mortality.
Describe the rationale and potential utility of TPE treatment in Trauma-Induced Coagulopathy (TIC).
Define the concept of "plasma failure" and the critical role plasma plays in regulating and maintaining thrombotic and immunologic homeostasis.